Bibliography
- Weening JJ : Advancing nephrology around the globe: an invitation to contribute.J. Am. Soc. Nephrol., 15, 2761–2762 (2004).
- Jones CA , KrolewskiAS, RogusJet al.: Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int., 67, 1684–1691 (2005).
- Chobanian AV , BakrisGL, BlackHRet al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206–1252 (2003).
- Cooper ME : Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.Diabetologia, 44, 1957–1972 (2001).
- Gnudi L , ThomasSM, VibertiG: Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism.J. Am. Soc. Nephrol., 18, 2226–2232 (2007).
- Jamerson KA : Preventing chronic kidney disease in special populations.Am. J. Hypertens., 18, 106S–111S (2005).
- Turnbull F , NealB, AlgertCet al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med., 165, 1410–1419 (2005).
- Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br. Med. J., 317, 703–713 (1998).
- Standards of medical care in diabetes – 2006. Diabetes Care, 29(Suppl. 1), S4–S42 (2006).
- Xue JL , FrazierET, HerzogCA, CollinsAJ: Association of heart disease with diabetes and hypertension in patients with ESRD.Am. J. Kidney Dis., 45, 316–323 (2005).
- Deckert T , Feldt-RasmussenB, Borch-JohnsenKet al.: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia, 32, 219–226 (1989).
- De Zeeuw D : Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?Kidney Int., 66(Suppl. 92), S2–S6 (2004).
- Gerstein HC , MannJF, YiQet al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 286, 421–426 (2001).
- Ruggenenti P , SchieppatiA, RemuzziG: Progression, remission, regression of chronic renal diseases.Lancet, 357, 1601–1608 (2001).
- Peterson JC , AdlerS, BurkartJMet al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med., 123, 754–762 (1995).
- Long DA , PriceKL, Herrera-AcostaJet al.: How does angiotensin II cause renal injury? Hypertension, 43, 722–723 (2004).
- De Vriese AS , StoenoiuMS, ElgerMet al.: Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int., 60, 202–210 (2001).
- Anderson S , VoraJP: Current concepts of renal hemodynamics in diabetes.J. Diabetes Complications, 9, 304–307 (1995).
- Raij L : The pathophysiologic basis for blocking the renin–angiotensin system in hypertensive patients with renal disease.Am. J. Hypertens., 18, 95S–99S (2005).
- Maddox DA , BrennerBM: Glomerular ultrafiltration. In: The Kidney. 6th edition. Brenner BM, Rector FC Jr (Eds). WB Saunders Company, PA, USA 319–374 (2000).
- Forbes JM , FukamiK, CooperME: Diabetic nephropathy: where hemodynamics meets metabolism.Exp. Clin. Endocrinol. Diabetes, 115, 69–84 (2007).
- Gnudi L , VibertiG, RaijLet al.: GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension, 42, 19–24 (2003).
- Inoki K , HanedaM, MaedaSet al.: TGFβ1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int., 55, 1704–1712 (1999).
- Weigert C , BrodbeckK, KlopferKet al.: Angiotensin II induces human TGF1β promoter activation: similarity to hyperglycaemia. Diabetologia, 45, 890–898 (2002).
- Ziyadeh FN : Mediators of diabetic renal disease: the case for TGFβ as the major mediator.J. Am. Soc. Nephrol., 15(Suppl. 1), S55–S57 (2004).
- Ziyadeh FN , SnipesER, WatanabeMet al.: High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am. J. Physiol., 259, F704–F714 (1990).
- Wolf G , SchroederR, ZiyadehFNet al.: High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am. J. Physiol., 273, F348–F356 (1997).
- Boffa JJ , LuY, PlacierSet al.: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol., 14, 1132–1144 (2003).
- Kato S , LuyckxVA, OtsMet al.: Renin–angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int., 56, 1037–1048 (1999).
- Epstein M : Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.Am. J. Kidney Dis., 37, 677–688 (2001).
- Iglarz M , TouyzRM, VielECet al.: Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin–angiotension system. Am. J. Hypertens., 17, 597–603 (2004).
- Ziyadeh FN , HoffmanBB, HanDCet al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA, 97, 8015–8020 (2000).
- Chow FY , Nikolic-PatersonDJ, OzolsEet al.: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int., 69, 73–80 (2006).
- Ferrara N , GerberHP, Le Couter J: The biology of VEGF and its receptors. Nat. Med., 9, 669–676 (2003)
- De Vriese AS , TiltonRG, ElgerMet al.: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol., 12, 993–1000 (2001).
- Sung SH , ZiyadehFN, WangAet al.: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol., 17, 3093–3104 (2006).
- Kuenen BC , LeviM, MeijersJCet al.: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol., 22, 1500–1505 (2002).
- Yang JC , HaworthL, SherryRMet al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 349, 427–434 (2003).
- Eremina V , CuiS, GerberHet al.: Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol., 17, 724–735 (2006).
- Mathieson PW : How much VEGF do you need?J. Am. Soc. Nephrol., 17, 602–603 (2006).
- Davis B et al. , Dei Cas A, Long DA : Podocyte-specific induced overexpression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J. Am. Soc. Nephrol., 18(8), 2320– 2329 (2007).
- Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet, 349, 1787–1792 (1997).
- K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: Am. J. Kidney Dis., 43, S1–S290 (2004).
- Allen TJ , CaoZ, YoussefSet al.: Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes, 46, 1612–1618 (1997).
- Yamagishi S , FukamiK, UedaSet al.: Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets, 8, 952–959 (2007).
- Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia, 39, 587–593 (1996).
- Katayama S , YagiS, YamamotoHet al.: Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens. Res., 30, 529–533 (2007).
- Rosario RF , PrabhakarS: Lipids and diabetic nephropathy.Curr. Diab. Rep., 6, 455–462 (2006).
- Rossing P : Prediction, progression and prevention of diabetic nephropathy. The Minkowski lecture 2005.Diabetologia, 49, 11–19 (2006).
- Fioretto P , SteffesMW, SutherlandDEet al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med., 339, 69–75 (1998).
- Mogensen CE , NeldamS, TikkanenIet al.: Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. Br. Med. J., 321, 1440–1444 (2000).
- Mogensen CE , VibertiG, HalimiSet al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension, 41, 1063–1071 (2003)
- Rossing P , HommelE, SmidtUMet al.: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia, 37, 511–516 (1994).
- Schmieder RE , KlingbeilAUet al., Fleischmann EH : Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J. Am. Soc. Nephrol., 16, 3038–3045 (2005).
- Gaede P , VedelP, LarsenNet al.: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med., 348, 383–393 (2003).
- Rossing P , HougaardP, ParvingHH: Risk factors for development of incipient and overt diabetic nephropathy in Type 1 diabetic patients: a 10-year prospective observational study.Diabetes Care, 25, 859–864 (2002).
- Gaede P , TarnowL, VedelPet al.: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with Type 2 diabetes and microalbuminuria. Nephrol. Dial. Transplant., 19, 2784–2788 (2004).
- Schjoedt KJ , RossingK, JuhlTRet al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int., 70, 536–542 (2006).
- O‘Brien E , BartonJ, NussbergerJet al.: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 49, 276–284 (2007).
- Kelly DJ , ZhangY, MoeGet al.: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 50, 2398–2404 (2007).
- Parving HH , LewisEJ, HollenbergNK: Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID). Presented at: Renal Week – American Society of Nephrology Meeting. San Francisco, CA, USA, October 31 – November 5 (2007).
- Neuhofer W , PittrowD: Role of endothelin and endothelin receptor antagonists in renal disease.Eur. J. Clin. Invest., 36(Suppl. 3), 78–88 (2006).
- Sasser JM , SullivanJC, HobbsJLet al.: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol., 18, 143–154 (2007).
- Tuttle KR , BastyrEJ, McGillJBet al.: Albuminuria and kidney function in a long-term study of ruboxistaurin for diabetic neuropathy. Presented at: Renal Week – American Society of Nephrology Meeting. San Francisco, CA, USA, October 31 – November 5 (2007).
- Gambaro G , van der Woude FJ: Glycosaminoglycans: use in treatment of diabetic nephropathy. J. Am. Soc. Nephrol., 11, 359–368 (2000).
- Gambaro G , KinalskaI, OksaAet al.: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric Type 1 and Type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol., 13, 1615–1625 (2002).
- King GL , BrownleeM: The cellular and molecular mechanisms of diabetic complications.Endocrinol. Metab. Clin. North Am., 25, 255–270 (1996).
- Gilbert RE , KimSA, TuttleKRet al.: Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and Type 2 diabetes. Diabetes Care, 30, 995–996 (2007)
- Kelly DJ , ZhangY, HepperCet al.: Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes, 52, 512–518 (2003).
- Thomas MC , ForbesJM, CooperME: Advanced glycation end products and diabetic nephropathy.Am. J. Ther., 12, 562–572 (2005).
- Williams ME : Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.Curr. Diab. Rep., 4, 441–446 (2004).
- Coughlan MT , Thallas-BonkeV, PeteJet al.: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology, 148, 886–895 (2007).
- Cooper ME , Jandeleit-DahmKA: Lipids and diabetic renal disease.Curr. Diab. Rep., 5, 445–448 (2005).
- Fujii M , InoguchiT, MaedaYet al.: Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int., 72, 473–480 (2007).
- Tojo A , AsabaK, OnozatoML: Suppressing renal NADPH oxidase to treat diabetic nephropathy.Expert. Opin. Ther. Targets, 11, 1011–1018 (2007).
- Osawa T , KatoY: Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.Ann. NY Acad. Sci., 1043, 440–451 (2005).
- Miyazaki Y , CersosimoE, TriplittCet al.: Rosiglitazone decreases albuminuria in Type 2 diabetic patients. Kidney Int., 72(11), 1367–1373 (2007).
- Pistrosch F , HerbrigK, KindelBet al.: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes, 54, 2206–2211 (2005).
- Sarafidis PA , BakrisGL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.Kidney Int., 70, 1223–1233 (2006).
- Dormandy JA , CharbonnelB, EcklandDJet al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366, 1279–1289 (2005).
- Home PD , PocockSJ, Beck-NielsenHet al.: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med., 357, 28–38 (2007).
- Nissen SE , WolskiK: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N. Engl. J. Med., 356, 2457–2471 (2007).